Concert Pharmaceuticals (NASDAQ:CNCE) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS
Concert Pharmaceuticals (NASDAQ:CNCE) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.13, Fidelity Earnings reports. Concert Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 7,303.34%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.35 million.
Shares of NASDAQ CNCE traded up $0.33 during mid-day trading on Friday, reaching $6.73. The company had a trading volume of 303,600 shares, compared to its average volume of 223,753. Concert Pharmaceuticals has a 1-year low of $5.36 and a 1-year high of $17.83. The company has a 50-day moving average price of $6.77 and a two-hundred day moving average price of $9.76. The stock has a market cap of $152.32 million, a PE ratio of -2.80 and a beta of 0.88. The company has a current ratio of 19.63, a quick ratio of 19.63 and a debt-to-equity ratio of 0.12.
In related news, Director Heek Christi Van purchased 5,000 shares of Concert Pharmaceuticals stock in a transaction on Tuesday, October 8th. The stock was bought at an average price of $5.90 per share, with a total value of $29,500.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $29,500. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 11.00% of the stock is owned by insiders.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Featured Article: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.